By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) 

11975 El Camino Real, Suite 101

San Diego  California  92130  U.S.A.
Phone: 858-792-6300 Fax: n/a


SEARCH JOBS

MEI Pharma is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's portfolio of drug candidates includes Pracinostat, a potential best-in-class, oral HDAC inhibitor currently in Phase II clinical studies for advanced hematologic diseases. The Company is also developing ME-344, a novel mitochondrial inhibitor that has shown evidence of clinical activity in refractory solid tumors, and ME-401 (formerly PWT143), a highly selective, oral PI3K delta inhibitor. For more information, please visit www.meipharma.com.

YEAR FOUNDED:

2000

LEADERSHIP:

CEO: Daniel Gold, PhD

CLINICAL TRIAL:

Please click here for clinical trial information.

JOB OPPORTUNITY:

Please click here for Mei Pharma job opportunities.


Key Statistics


Email: meiinformation@meipharma.com
Ownership: Subsidiary

Web Site: MEI Pharma
Employees:
Symbol: MEIP
 



Industry
Pharmaceutical






Company News
San Diego's MEI Pharma (MEIP) Forges $184 Million Cancer Deal With Presage Biosciences 9/6/2017 6:56:44 AM
MEI Pharma (MEIP) Reports Fiscal Year 2017 Results 9/5/2017 10:29:51 AM
MEI Pharma (MEIP) To Present At Two Upcoming Investor Conferences 8/31/2017 11:24:13 AM
MEI Pharma (MEIP) To Host Fiscal Year End Conference Call On September 5, 2017 8/29/2017 8:59:23 AM
Helsinn And MEI Pharma (MEIP) Announce First Patient Dosed In Pivotal Phase III Study Of Pracinostat And Azacitidine In Acute Myeloid Leukemia 8/2/2017 8:24:45 AM
Helsinn And MEI Pharma (MEIP) Announce First Patient Dosed In Phase II Dose-Optimization Study Of Pracinostat And Azacitidine In Myelodysplastic Syndrome 6/14/2017 6:50:07 AM
Helsinn And MEI Pharma (MEIP) Report Correlation Between Mutations In DNA Methylation Pathway And Clinical Response In Phase II Study Of Pracinostat And Azacitidine In Acute Myeloid Leukemia 6/5/2017 7:45:18 AM
MEI Pharma (MEIP) Announces Pre-Specified Response Rate Exceeded In Dose-Escalation Study Of ME-401 In Chronic Lymphocytic Leukemia And Follicular Lymphoma 5/31/2017 7:06:56 AM
Can MEI Pharma (MEIP) Rise Nearly 300%? 5/26/2017 5:55:44 AM
MEI Pharma (MEIP) Reports Third Quarter Fiscal Year 2017 Results 5/4/2017 10:10:01 AM
12345678910...
//-->